Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Pediatric Systemic Juvenile Idiopathic Arthritis (SELECT-sJIA)
NCT05609630Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of upadacitinib in systemic juvenile idiopathic arthritis (SJIA) (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 30 Response at 12 weeks and Number of Participants with Adverse Events at 52 weeks. Started Oct 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT05609630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609630.